Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
OncoC4, Inc.
This is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC-392 is an antibody drug that regulates the immune system to treat cancer. This type of treatment is called immunotherapy.
Enrollment Form
This study is currently enrolling.